Boston Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTHE research report →
Companywww.bostonti.com
Boston Therapeutics, Inc. , a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications.
- CEO
- Chi-Heng Cheng
- IPO
- 2012
- HQ
- Lawrence, MA, US
Valuation
- Market Cap
- $0
- P/E
- -1.22
- P/S
- 0.00
- P/B
- -0.13
- EV/EBITDA
- -10.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -243.20%
- Op Margin
- -8418.32%
- Net Margin
- -9724.54%
- ROE
- 11.17%
- ROIC
- 20.99%
Growth & Income
- Revenue
- $9.34K · -42.83%
- Net Income
- $-907,883 · 75.42%
- EPS
- $-0.01 · 77.22%
- Op Income
- $-785,934
- FCF YoY
- 34.42%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- -0.78
- Avg Volume
- 169.80K
Get TickerSpark's AI analysis on BTHE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 2, 18 | RAUSCH CARL W | buy | 2,000,000 |
| Feb 2, 18 | RAUSCH CARL W | buy | 1,000,000 |
| Sep 15, 11 | RAUSCH CARL W | other | 1,500,000 |
| Aug 12, 16 | RAUSCH CARL W | other | 6,000,000 |
| Mar 25, 15 | RAUSCH CARL W | other | 500,000 |
| May 15, 15 | CONAWAY DALE H | buy | 5,000 |
| May 15, 15 | PLATT DAVID | buy | 1,000 |
| May 14, 15 | PLATT DAVID | buy | 5,000 |
| Sep 25, 14 | ESBER HENRY JEMIL | other | 6,000 |
| Mar 18, 15 | ESBER HENRY JEMIL | buy | 9,000 |
Our BTHE Coverage
We haven't published any research on BTHE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BTHE Report →